|
|
- The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
|
|
|
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Sales forecast by analysts have been recently revised upwards.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
|
|
|
- The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
- Technically, the stock approaches a strong medium-term resistance at CNY 357.
- With an expected P/E ratio at 113.03 and 81.49 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
|
|
|
| Sales 2020 |
446 M
68,9 M
68,9 M
|
| Net income 2020 |
201 M
31,0 M
31,0 M
|
| Net cash 2020 |
1 009 M
156 M
156 M
|
| P/E ratio 2020 |
113x |
| Yield 2020 |
0,25% |
|
| Capitalization |
22 601 M
3 496 M
3 497 M
|
| EV / Sales 2020 |
48,5x |
| EV / Sales 2021 |
33,7x |
| Nbr of Employees |
387 |
| Free-Float |
28,8% |
|
Upcoming event on SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
- |
| Finances |
- |
| Profitability |
|
| Earnings quality |
- |
| Business Predictability |
|
| P/E ratio |
|
| Potential |
|
| Yield |
|
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
